Expression assessment was done using Kallisto v0.51.1[PMID: 27043002] with ENSEMBLv103 annotation of the Human genome and differential expression analyses was perfomred using R4.4.1 and sleuth v0.30.1
we performed a genome-wide synthetic lethal screen, using CRISPR-Cas9 genome editing, to identify potential therapeutic targets specific for ATRX-mutated cancers. In isogenic hepatocellular carcinoma
To dig out the synthetic lethality targets of mitomycin C, we we performed Genome-scale CRISPR-Cas9 knockout screening in SNU-1 with 0.1% DMSO or 0.3 µM MMC for 14 days. We found that BRCA2 is a synth
